Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) -- The "India Clinical Trials Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.
India Clinical Trials Market was valued at USD 2.05 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.64% through 2030
The Clinical Trials Market refers to the global industry involved in the operation and management of clinical trials, which are crucial research investigations. In these trials, individuals voluntarily participate to test new treatments, interventions, or tests that aim to prevent, detect, treat, or manage various diseases or medical conditions. By conducting these trials, researchers aim to determine not only the safety and effectiveness but also the scalability of new drugs or treatments, ensuring their potential impact on a larger scale. 
This market encompasses a wide range of stakeholders, including pharmaceutical companies, contract research organizations, healthcare providers, academic institutes, and more. All these entities collaborate in a concerted effort, playing a pivotal role in accelerating the process of drug discovery and development. Through their collective endeavors, innovative treatments can be made available to patients worldwide, addressing unmet medical needs and improving health outcomes across diverse populations. This continuous pursuit of knowledge and advancements in clinical research ultimately leads to breakthroughs that shape the future of medicine and benefit humanity as a whole.
Adoption Of New Technology in Clinical Research
The adoption of new technology in clinical research is fueling an exponential increase in the demand for clinical trials in India. The introduction of cutting-edge technologies such as Artificial Intelligence (AI), Machine Learning (ML), and blockchain has not only transformed but revolutionized the clinical research landscape in the country. These advanced technologies have proven to be game-changers, expediting the process of data collection, enhancing data accuracy, and streamlining trial management, thereby significantly increasing efficiency and reducing costs.
The tech-driven approach has made India an exceptionally attractive destination for global pharmaceutical companies and Contract Research Organizations (CROs) seeking to conduct clinical trials. The integration of advanced technologies in clinical research has not only enhanced data reliability but has also resulted in faster trial completion times, leading to quicker regulatory approvals. This, in turn, further incentivizes more trials to be conducted in the country. India's diverse genetic pool adds another layer of advantage, making it an ideal location for conducting diverse clinical studies. The ability to include a wide range of genetic profiles in clinical trials allows for more comprehensive insights and contributes to the growing demand for clinical research in India.
The integration of technology in clinical research is not just a passing trend; it signifies a paradigm shift that is paving the way for more agile, precise, and patient-centric clinical trials in India. This transformative shift holds immense potential for advancing medical knowledge, improving patient outcomes, and ultimately shaping the future of healthcare in the country.
Digitalization Of Clinical Trials
The digitalization of clinical trials is expected to have a positive and transformative impact on market growth. With the advancement of digital technologies, multiple trial processes such as data capture, regulatory compliance, logistics and supplies management, and more, have been streamlined, leading to increased efficiency and effectiveness. This digital revolution has revolutionized the way clinical trials are conducted, allowing for real-time data acquisition related to safety and toxicity. The ability to rectify any issues promptly in trial design has further facilitated market growth.
In addition to the numerous benefits of digitalization, it is worth noting that the cost of clinical trials in India is nearly half of that incurred in the U.S. and Europe. This significant cost efficiency not only attracts global pharmaceutical companies but also creates a favorable environment for conducting clinical trials within the country. India offers a large treatment-naive patient pool, which is highly valuable for conducting rigorous and diverse clinical studies. These factors, combined, contribute to the overall growth of the market and position India as a prominent destination for clinical research and development.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 80 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value (USD) in 2025 | $2.05 Billion |
| Forecasted Market Value (USD) by 2030 | $3.37 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | India |
Report Scope:
Competitive Landscape
- IQVIA RDS (India) Private Limited
- PAREXEL International (India) Private Ltd
- Icon Clinical Research India Pvt Ltd
- Veeda Clinical Research Limited
- Aragen Life Sciences Ltd.
- Abiogenesis Clinpharm Pvt Ltd
- Cliantha Research Limited
India Clinical Trials Market, By Phase:
- Phase I
- Phase II
- Phase III
- Phase IV
India Clinical Trials Market, By Study Design:
- Interventional
- Observational
- Expanded Access
India Clinical Trials Market, By Indication:
- Autoimmune
- Blood Disorders
- Pain Management
- Oncology
- CNS Condition
- Diabetes
- Obesity
- Cardiovascular
- Others
India Clinical Trials Market, By Region:
- North
- South
- West
- East
For more information about this report visit https://www.researchandmarkets.com/r/f3w0kx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
